Search results
This study found that the overall risk of breast cancer among hormonal contraceptive users is low. Because of the low baseline risks in the age groups using hormonal contraception (ie, premenopausal women), the risk difference between hormonal contraception users and nonusers is small.
23 wrz 2022 · Among women receiving tamoxifen, off-label use of the levonorgestrel-releasing IUD has been suggested as an alternative contraceptive method because no evidence of worsening cancer outcomes has been reported. 43 However, this approach has been used more frequently as a means to protect the endometrium during tamoxifen treatment rather than as a ...
8 mar 2022 · Breast cancer (BC) was the most common type of cancer in women in the world in 2020. The relationship between LNG-IUS and BC is controversial. We conducted an updated meta-analysis (larger sample capacity and including Asian data) to explore whether LNG-IUS can increase the risk of BC. Study design.
16 paź 2024 · Breast Cancer in Users of Levonorgestrel-Releasing Intrauterine Systems. JAMA. 2024 Oct 16. doi: 10.1001/jama.2024.18575.
Studies reporting breast cancer risk estimates among healthy users of LNG-IUS were included according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analysis) criteria. Two authors performed data extraction, and a third author resolved disagreements.
7 gru 2017 · We assessed associations between the use of hormonal contraception and the risk of invasive breast cancer in a nationwide prospective cohort study involving all women in Denmark between 15...
21 mar 2023 · We carried out a nested case–control study in the Clinical Practice Research Datalink (CPRD), including almost 10,000 women aged <50 years with breast cancer, to assess the relationship between a woman’s recent use of hormonal contraceptives and her subsequent risk of breast cancer.
